GlassScriptPhysician profile
Cile H Williamson
NPI 1831113935
$2,447.08
in general payments reported to CMS, 2019-2025
29 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $167 · 2021: $273 · 2022: $135 · 2023: $541 · 2024: $473 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $289.83 | 2019-2021 | |
| Astellas Pharma US INC | $232.24 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $210.71 | 2023-2025 | Gemtesa, Myfembree |
| Myriad Women'S Health, INC. | $206.63 | 2023 | Myrisk |
| Coopersurgical, INC. | $200.24 | 2020-2025 | Paragard T 380a, Paragard T 380a, Endosee |
| Lilly USA, LLC | $125.00 | 2024 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $123.76 | 2019-2021 | |
| Pfizer INC. | $118.94 | 2019-2020 | |
| Abbvie INC. | $107.50 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Shield Therapeutics INC | $99.94 | 2023-2025 | Accrufer |
| Avion Pharmaceuticals | $90.42 | 2019-2022 | |
| Lupin INC. | $75.23 | 2019 | |
| Mayne Pharma Commercial LLC | $66.96 | 2023-2025 | |
| Amag Pharmaceuticals, INC. | $63.51 | 2019 | |
| Therapeuticsmd, INC. | $54.66 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $53.74 | 2019-2023 | Slynd |
| Myovant Sciences INC. | $52.91 | 2022 | |
| Hologic Sales and Service, LLC | $49.64 | 2025 | Aptima, Thinprep 2000 Processor |
| Agile Therapeutics, INC. | $44.99 | 2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $40.78 | 2020-2025 | |
| Duchesnay USA Incorporated | $28.56 | 2019 | |
| Minerva Surgical, INC | $24.70 | 2019-2024 | |
| Evofem Biosciences, INC. | $16.83 | 2021 | |
| Urovant Sciences INC | $16.61 | 2022 | |
| Exact Sciences Corporation | $15.17 | 2025 | The Cologuard Plus Collection Kit |
| Millicent US INC | $13.68 | 2025 | Femlyv |
| Aspira Women'S Health INC | $13.12 | 2024 | Ova1 |
| Daiichi Sankyo INC. | $10.78 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cile Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.